second generation program (Kesios Therapeutics)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug Namesecond generation program (Kesios Therapeutics)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionGrowth arrest and DNA damage-inducible protein GADD45 beta inhibitorsExtracellular-signal-regulated kinase 5 inhibitors
TargetsExtracellular-signal-regulated kinase 5Growth arrest and DNA damage-inducible protein GADD45 beta
Therapy Area/IndicationsMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesKesios Therapeutics Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesKesios Therapeutics Ltd
Active IndicationsN/A
Inactive IndicationsMultiple Myeloma

Other Information

ATC CodeN/A
Related LinksN/A